For the half-year to 31 December 2014, the IPKat's regular team is supplemented by contributions from guest bloggers Rebecca Gulbul, Lucas Michels and Marie-Andrée Weiss.

Regular round-ups of the previous week's blogposts are kindly compiled by Alberto Bellan.

Wednesday, 12 October 2005

STOP PRESS: LIPITOR RULING


The ruling

The Patents Court (Mr Justice Pumfrey) has today handed down its judgment in the eagerly-watched contest between Ranbaxy and Pfizer over the latter's LIPITOR patents. The decision was a surprise (according to some) win for Pfizer, which retains its monopoly right in the UK till 2011. At the time of posting this news item, the full text of Pumfrey J's decision had not yet been posted on BAILII or on any of the subscription services. Ranbaxy has already said it proposed to appeal.

The IPKat says this is a good decision for the UK's patents professions. In the past, the UK Patents Court has been perceived as anti-patent, but decisions like this will make patentees feel more confident about having their IP rights litigated in London. Not so fast, adds Merpel - if the case goes to the Court of Appeal, we should remember that Lord Justice Jacob has taken some robustly different views to those held by Pumfrey J, for example in Reed v Reed.

News here from Bloomberg, MSN Money and Reuters.

Background

Ranbaxy sought to invalidate Pfizer's UK patents on anti-cholesterol medicine LIPITOR, which has a $11 billion annual turnover. Pfizer has already lost a similar action brought by Ranbaxy in Austria; Deutsche Bank analysts placed an 80 percent probability on the same result occurring in the UK too.

The UK market for LIPITOR represents nearly 7 percent of that product's global sales. A defeat would however shake confidence in Pfizer's patent position in the far more important US market, where Ranbaxy is also challenging the patent. If Ranbaxy wins in the United States, Pfizer could face generic competition there by 2007, four years earlier than if the patents are upheld, punching a large hole in the group's future earnings.

6 comments:

Anonymous said...

Regarding the Deutsche Bank prediction, it would seem that not all analysts were of the same opinion. At Forbes.com, the following was reported:
"Timothy Anderson, an analyst at Prudential Equity Group, wrote yesterday in a note to investors that New York-based Pfizer, the world’s largest drug firm, is likely to win on both patents. He put the odds of a Pfizer win at 65% for the more critical of the two patents, and 50% on the second. Ranbaxy would probably have to win both to launch the drug soon."
It would appear that there are analysts and analysts.

Anonymous said...

The decision is now on BAILII:

http://www.bailii.org/ew/cases/EWHC/Patents/2005/2142.html

Anonymous said...

Nice post. I think that your words are very interesting. I don´t agree with you in some aspect, but in general i think the same. See Her Squirt Bang Bus

Anonymous said...

Great blog, I also have a casino related site, If you want or need more exposure get casino related traffic by the thousands at **casino traffic** Works for me!

Anonymous said...

I discuss this topic daily myself. I also have a website that talks about business fast make make make money money money online opportunity related things. Go check it out if you get a chance.

Anonymous said...

"No Charge Online Advertising Channels For Any Business"

Subscribe to the IPKat's posts by email here

Just pop your email address into the box and click 'Subscribe':